TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04725331

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BT-001
Description: Oncolytic Vaccinia virus containing genes encoding the 4-E03 human recombinant anti-hCTLA4 antibody and human GM-CSF administered at different dose \[Phase I, Part A\]; one dose lower and at Recommended Dose for Part B \[Phase I, Part B\] by intra-tumoral (IT) route.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BT-001
Description: Oncolytic Vaccinia virus containing genes encoding the 4-E03 human recombinant anti-hCTLA4 antibody and human GM-CSF administered at different dose \[Phase I, Part A\]; one dose lower and at Recommended Dose for Part B \[Phase I, Part B\] by intra-tumoral (IT) route.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BT-001
Description: Oncolytic Vaccinia virus containing genes encoding the 4-E03 human recombinant anti-hCTLA4 antibody and human GM-CSF administered at different dose \[Phase I, Part A\]; one dose lower and at Recommended Dose for Part B \[Phase I, Part B\] by intra-tumoral (IT) route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab [KEYTRUDA®]
Description: Programmed death receptor (PD-1) blocking antibody administered at 200mg by intravenous (IV) infusions every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab [KEYTRUDA®]
Description: Programmed death receptor (PD-1) blocking antibody administered at 200mg by intravenous (IV) infusions every 3 weeks.
Study: NCT06169020

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Resting and maximal oxygen consumtion
Description: All subjects will undergo tests for resting and maximal oxygen consumption while simoultaneously wearing a number of wearables and a heart rate monitor. They will also be tested for health related physical fitness and resting blood pressure. Their body composition will also be measured.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Free living energy expenditure
Description: All subjects will ingest a dose of doubly labelled water after which they will be fitted with several wearables. They will live their ordinary lives except that they will collect daily urine samples.
Study: NCT06390124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platelet Derived Growth Factor (PDGF)
Description: Reconstructive therapy of advanced peri-implantitis-related defects with anorganic bovine bone and allograft combined with PDGF
Study: NCT05341115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprorelin Acetate Depot 3M
Description: Leuprorelin Acetate Depot 3M SC injections.
Study: NCT06234930

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Audiovisual stimulation VR system
Description: Delivery of synchronized auditory and visual stimuli at varying frequencies via a VR headset.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Audiovisual stimulation VR system
Description: Delivery of synchronized auditory and visual stimuli at varying frequencies via a VR headset.
Study: NCT05711069

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Core Stability Exercise Program
Description: Core stability is an important component maximising efficient athletic function. Function is most often produced by the kinetic chain, the coordinate sequenced activation of body segments that places the distal segment in the optimum position at the optimum velocity with the optimum timing to produce the desired athletic task. Speed and power are critical performance factors in football. Football including jumping, kicking, tackling, turning, sprinting, changing pace, and sustaining forceful contractions to maintain balance and control of the ball against defensive pressure. İn the literature, no study has demonstrated the effectiveness of core stability exercise program in adolescent football players.

Intervention type: OTHER
Group type: OTHER
Intervention: Routine Football Training Program
Description: Core stability is an important component maximising efficient athletic function. Function is most often produced by the kinetic chain, the coordinate sequenced activation of body segments that places the distal segment in the optimum position at the optimum velocity with the optimum timing to produce the desired athletic task. Speed and power are critical performance factors in football. Football including jumping, kicking, tackling, turning, sprinting, changing pace, and sustaining forceful contractions to maintain balance and control of the ball against defensive pressure. İn the literature, no study has demonstrated the effectiveness of core stability exercise program in adolescent football players.
Study: NCT04696068

Intervention type: OTHER
Intervention: Porcelain plates
Description: The patients will receive the same food in another presentation : porcelain plates instead of plastic trays
Study: NCT06136533

Intervention type: OTHER
Intervention: Assessment-OHS
Description: Demographic information of individuals diagnosed with OHS without sarcopenia risk is recorded.Bioelectrical Impedance Analysis is used to analyze body composition.The comorbidity levels of the patients were assessed with the 'Modified Charlson Comorbidity Index',sleep quality was assessed with 'Polysomnography' and 'Pittsburgh Sleep Quality Index' and daytime sleepiness was assessed with the 'Epworth Sleepiness Scale'.The assessment of exercise capacity is performed with the 'Six Minute Walking Test' and the assessment of respiratory muscle strength is performed with the 'Electronic Intraoral Pressure Measurement Device'.Patients' physical activity levels are monitored with a pedometer.Quadriceps muscle strength is measured with Hand-held dynamometer and grip strength is measured with Jamar hand dynamometer. The presence of depression is assessed with the 'Beck Depression Inventory' and quality of life with 'Nottingham Health Profile' and 'Functional Outcomes of Sleep Questionnaire'.

Intervention type: OTHER
Intervention: Assessment-Sarcopenic Obesity With OHS
Description: The sarcopenia diagnostic algorithm is used as a reference in the assessment of the presence of sarcopenic obesity. Demographic information of patients diagnosed with sarcopenic obesity is recorded. Then, the comorbidity levels of the patients were assessed with the 'Modified Charlson Comorbidity Index', sleep quality was assessed with 'Polysomnography' and 'Pittsburgh Sleep Quality Index', and daytime sleepiness was assessed with the 'Epworth Sleepiness Scale'. The assessment of exercise capacity is performed with the 'Six Minute Walking Test' and the assessment of respiratory muscle strength is performed with the 'Electronic Intraoral Pressure Measurement Device'. Patients' physical activity levels are monitored with a pedometer. Quadriceps muscle strength is measured with Hand-held dynamometer. The presence of depression is assessed with the 'Beck Depression Inventory' and quality of life with the 'Nottingham Health Profile' and the 'Functional Outcomes of Sleep Questionnaire'.
Study: NCT06407323

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Personalized vibration therapy powered by AI
Description: A target frequency of either 20 Hz or 25 Hz, and amplitude 2-4 mm The whole treatment session will be around 20 minutes along with hot pack as a baseline treatment, consisted of 6 sessions per week for total 8 weeks of duration

Intervention type: OTHER
Group type: OTHER
Intervention: Physical therapy treatment
Description: A selected physical therapy treatment program for spastic diplegic CP.
Study: NCT05569681

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bemiparin 3500
Description: Bemiparin sodium 3,500 IU anti Xa/0.2 ml solution for injection in the pre-filled syringe will be provided for each patient in one group; subcutaneously 6 hours after the surgery(orthopedic and non-orthopedic) and then daily for up to 10 days for moderate and high - risk group and for 30 days in very high risk-group patients according to Caprinin risk classification for venous thromboembolism.~Other Name: Hibor; Laboratories Rovi Pharmaceuticals

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bemiparin 5000 IU
Description: Bemiparin sodium 5000 IU anti Xa/0.2 ml solution for injection in the pre-filled syringe will be provided for each patient in one group; subcutaneously 6 hours after the surgery(orthopedic and non-orthopedic) and then daily for up to 10 days for moderate and high - risk group and for 30 days in very high risk-group patients according to Caprinin risk classification for venous thromboembolism.~Other Name: Hibor; Laboratories Rovi Pharmaceuticals
Study: NCT06514118

Intervention type: RADIATION
Intervention: residual tumor irradiation
Description: lung residual tumor will be given external beam irradiation for 50GY in 25 fractions in total
Study: NCT06120179

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Bashir™ Endovascular Catheter (BEC
Description: To demonstrate the efficacy and safety of the Bashir™ Endovascular Catheter for the administration of pharmaco-mechanical catheter directed therapy using pulse spray of r-tPA for the treatment of acute submassive pulmonary embolism.
Study: NCT06258538

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bilateral task-oriented therapy
Description: The functional training tasks emphasize UE movements (gross or fine motor tasks) involved in daily activities but focus on both UEs moving synchronously, such as opening 2 closet doors, grasping and releasing 2 towels, wiping the table with 2 hands, and so on. The activities can also be graded in terms of difficulty and task requirements, according to the impairment level and the progression of the UE of each participant.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral task-oriented therapy
Description: The functional training tasks emphasize UE movements (gross or fine motor tasks) involved in daily activities but focus on both UEs moving synchronously, such as opening 2 closet doors, grasping and releasing 2 towels, wiping the table with 2 hands, and so on. The activities can also be graded in terms of difficulty and task requirements, according to the impairment level and the progression of the UE of each participant.
Study: NCT05565248

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: VCTX211
Description: CRISPR-Cas9 genetically modified PEC211 cells loaded into a delivery device
Study: NCT05818228

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video
Description: A short video aimed at reducing self-stigma among individuals with a history of childhood maltreatment and increasing their help seeking intentions (if needed).
Study: NCT06465862

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TruTag System
Description: TruTag technology system, consisting of microparticle-tagged Biktarvy and companion smartphone app.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biktarvy Pill
Description: Biktarvy prescribed with TruTag system and tagged with TruTag microparticles.
Study: NCT05125471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Adult dosing (\>/= 18 years old) will be 60 mg orally once daily (tablet formulation); Pediatric dosing (\<18 years old) will be 1 mg/kg/dose (maximum 60 mg per dose) orally once daily (oral suspension formulation).
Study: NCT05653479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UPB-101
Description: UPB-101 Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UPB-101
Description: UPB-101 Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UPB-101
Description: UPB-101 Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UPB-101
Description: UPB-101 Subcutaneous injection
Study: NCT06400186

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity gait training in varying external environments
Description: Participants will engage in two 45-minutes treadmill-based gait training sessions. These training sessions will occur on separate days. One session will be performed in a natural unmodified environment. One session will be performed in a movement amplification environment. The goal of each session will be to achieve 40-minutes of walking within a target heart rate range of 70-85% of estimated heart rate max. Each session will begin and end with a 2.5 minute warm-up and cool down respectively. Participants will be given rest breaks as needed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treadmill walking in varying external environments
Description: Participants will perform a series of treadmill walking trials. Each trial will consist of 400 total steps. The first 100 steps will be performed in a natural unmodified environment. The next 200 steps will be performed in 1 of 3 external environments (natural unmodified, movement amplification, or unpredictable lateral perturbations). The final 100 steps will be performed in a natural unmodified environment. Participants will be given rest breaks between trials.
Study: NCT05395117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5462
Description: Treatment Arm A: Participants will receive the IMP, AZD5462 Dose A starting on Day 6 and continued until Day 18 and the following approved medicinal products:~* Midazolam~* Rosuvastatin~* Digoxin~Treatment Arm B: Participants will receive the IMP, AZD5462 Dose B starting on Day 6 and continued until Day 18 and the following approved medicinal products:~* Midazolam~* Rosuvastatin~* Digoxin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5462
Description: Treatment Arm A: Participants will receive the IMP, AZD5462 Dose A starting on Day 6 and continued until Day 18 and the following approved medicinal products:~* Midazolam~* Rosuvastatin~* Digoxin~Treatment Arm B: Participants will receive the IMP, AZD5462 Dose B starting on Day 6 and continued until Day 18 and the following approved medicinal products:~* Midazolam~* Rosuvastatin~* Digoxin
Study: NCT05812482

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Drug balloon dilatation
Description: The Drug balloon is covered with paclitaxel coating that diffuses the drug into the urethral wall when dilated

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Direct vision internal urethrotomy (DVIU)
Description: A control subject will choose DVIU surgery until the desired effect is achieved
Study: NCT05900024

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Funk It Cycle Bites
Description: The intervention product contains: Organic Pumpkin Seed Butter, Prebiotic Agave Inulin, Organic Flax Seed, Organic Oat Flour, Organic Ginger, Quinoa Sprouts, Crispy Red Rice, Organic Cacao Nibs, Sunflower Seed Butter, Organic Reishi Mushroom, Organic Amaranth Seeds, Dates, Organic Button Mushroom, Acai Berry, Amla Fruit, Goji Berry, Pomegranate, Cranberry, Acerola (Cherry Juice), Rosemary Extract, Vitamin E (Mixed Tocopherols), Organic Vanilla Extract, Sea Salt, Cinnamon, Naturally Sourced Potassium Sorbate.
Study: NCT06202261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2930 for injection
Description: TQB2930 for injection is a HER2 bispecific antibody.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2930 for injection
Description: TQB2930 for injection is a HER2 bispecific antibody.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2930 for injection
Description: TQB2930 for injection is a HER2 bispecific antibody.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2930 for injection
Description: TQB2930 for injection is a HER2 bispecific antibody.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel for injection (albumin-bound)
Description: It is an anti-microtubule chemotherapy drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB3616 capsule
Description: TQB3616 capsule is a Cyclin-dependent kinase 4/6 (CDK4/6) inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant injection
Description: Fulvestrant is a competitive estrogen receptor antagonist with similar affinity to estradiol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine tablets
Description: Capecitabine is converted to 5-fluorouracil (5-FU) by in vivo enzyme action.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine tartrate injection
Description: Vinorelbine is an anti-tumor drug of vinca alkaloids.
Study: NCT06514924

Intervention type: OTHER
Intervention: height and weight measurement
Description: Height and weight measurements and socioeconomic status survey

Intervention type: OTHER
Intervention: height and weight measurement
Description: Height and weight measurements and socioeconomic status survey
Study: NCT05467709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: 2 mg Day 1 and Day 16

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-543
Description: 12 mg q12 hour for 14 consecutive days starting on Day 3
Study: NCT05582200

Intervention type: DIAGNOSTIC_TEST
Intervention: Positron Emission Tomography (PET) using two PET tracer under IND
Description: Positron Emission Tomography

Intervention type: DIAGNOSTIC_TEST
Intervention: Positron Emission Tomography (PET) using two PET tracer under IND
Description: Positron Emission Tomography
Study: NCT05077683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 MG [Xarelto]
Description: Experimental group: usual DAPT strategy (aspirin (≤100mg per day), clopidogrel (75mg per day) or ticagrelor (90mg twice daily)) + rivaroxaban 2.5mg twice daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DAPT strategy
Description: usual DAPT strategy (aspirin (≤100mg per day), clopidogrel (75mg per day) or ticagrelor (90mg twice daily)) +

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAPT strategy
Description: usual DAPT strategy (aspirin (≤100mg per day), clopidogrel (75mg per day) or ticagrelor (90mg twice daily)) +
Study: NCT06023303

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Potenza
Description: The Radiofrequency microneedling device will be used for treating several skin problems. It is mostly used on the face and neck, specifically to treat jowls and firm the jawline, under aye area, and around the mouth.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Potenza
Description: The Radiofrequency microneedling device will be used for treating several skin problems. It is mostly used on the face and neck, specifically to treat jowls and firm the jawline, under aye area, and around the mouth.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Morpheus
Description: The Radiofrequency microneedling device will be used for treating several skin problems. It is mostly used on the face and neck, specifically to treat jowls and firm the jawline, under aye area, and around the mouth.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Morpheus
Description: The Radiofrequency microneedling device will be used for treating several skin problems. It is mostly used on the face and neck, specifically to treat jowls and firm the jawline, under aye area, and around the mouth.
Study: NCT05066347

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiophone Plus
Description: Cardiophone Plus (Bittium Faros 360 Mobile event recorder, Bittium Biosignals Ltd., Finland., an external loop recorder with 3 leads for 2 channels. Cardiophone Plus evaluates all cardiac beats and rhythm abnormalities that are detected as per the algorithm programmed into the device. These abnormalities are then automatically and immediately transmitted to a central monitoring station without the need for any patient intervention (device-triggered transmission). This transmission occurs through the cell phone that comes with the device. The central monitoring station is in Windsor, Ontario (Canadian Cardiac Care) and is staffed round the clock by certified electrocardiographic technicians and a cardiologist on-call.
Study: NCT06567236

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3D software
Description: Participants in the experimental arm will receive extra training on Planmeca Romexis Compare Software adapted to evaluate endodontic access preparation.
Study: NCT06057233

Intervention type: DIAGNOSTIC_TEST
Intervention: mqMRI and GABA-MRS
Description: multiparametric quantitative MRI (mqMRI) and of GABA-edited magnetic resonance spectroscopy (GABA-MRS)
Study: NCT06202261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin mesylate injection
Description: Eribulin induces G2/M phase cell cycle arrest, mitotic spindle division, and ultimately apoptosis after prolonged mitotic arrest through its tubulin-based anti-mitotic mechanism.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride for injection
Description: Gemcitabine is a cell cycle specific anti-metabolic anticancer agent
Study: NCT06573346

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cervical spinal stabilization exercise
Description: The cervical region is one of the most affected regions of the musculoskeletal system due to the intensive proprioceptors. Studies have shown that many position sense proprioceptors are over the deep group cervical muscles such as longus colitis and longus capitis. The deep group cervical muscles, which perform a dynamic ligament function, have an important role in maintaining the stability of the spine as well as the proprioceptive sense. In particular, proprioceptive receptors, which are commonly found in the deep suboccipital muscles; There are cervical and reflex connections with vestibular, visual and postural control systems.
Study: NCT05395117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Participants will receive a single dose of midazolam in the morning of Day 1 and in the morning of Day 15 in both the arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Participants will receive a single dose of midazolam in the morning of Day 1 and in the morning of Day 15 in both the arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Participants will receive rosuvastatin as a single dose administered with digoxin at the same time in the morning of Day 2, Day 6, and in the morning of Day 16 in both the arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Participants will receive rosuvastatin as a single dose administered with digoxin at the same time in the morning of Day 2, Day 6, and in the morning of Day 16 in both the arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Participants will receive digoxin as a single dose administered with rosuvastatin at the same time in the morning of Day 2, Day 6, and in the morning of Day 16 in both the arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Participants will receive digoxin as a single dose administered with rosuvastatin at the same time in the morning of Day 2, Day 6, and in the morning of Day 16 in both the arms.